Autopsy Prevalence of Tuberculosis and Other Potentially Treatable Infections among Adults with Advanced HIV Enrolled in Out-Patient Care in South Africa. by Karat, Aaron S et al.
Karat, AS; Omar, T; von Gottberg, A; Tlali, M; Chihota, VN; Church-
yard, GJ; Fielding, KL; Johnson, S; Martinson, NA; McCarthy, K;
Wolter, N; Wong, EB; Charalambous, S; Grant, AD (2016) Autopsy
Prevalence of Tuberculosis and Other Potentially Treatable Infections
among Adults with Advanced HIV Enrolled in Out-Patient Care in
South Africa. PLoS One, 11 (11). e0166158. ISSN 1932-6203 DOI:
10.1371/journal.pone.0166158
Downloaded from: http://researchonline.lshtm.ac.uk/3071548/
DOI: 10.1371/journal.pone.0166158
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
RESEARCH ARTICLE
Autopsy Prevalence of Tuberculosis and
Other Potentially Treatable Infections
among Adults with Advanced HIV Enrolled in
Out-Patient Care in South Africa
Aaron S. Karat1*, Tanvier Omar2, Anne von Gottberg3,4, Mpho Tlali5, Violet N. Chihota5,6,
Gavin J. Churchyard1,5,6, Katherine L. Fielding1,6, Suzanne Johnson7, Neil
A. Martinson8,9,10, Kerrigan McCarthy5,6,11, Nicole Wolter3,4, Emily B. Wong12,13,
Salome Charalambous5,6, Alison D. Grant1,6,12,14
1 TB Centre, London School of Hygiene & Tropical Medicine, London, United Kingdom, 2 Department of
Anatomical Pathology, National Health Laboratory Service and University of the Witwatersrand,
Johannesburg, South Africa, 3 Centre for Respiratory Diseases and Meningitis, National Institute for
Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa, 4 School
of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa,
5 The Aurum Institute, Johannesburg, South Africa, 6 School of Public Health, Faculty of Health Sciences,
University of the Witwatersrand, Johannesburg, South Africa, 7 Foundation for Professional Development,
Pretoria, South Africa, 8 Perinatal HIV Research Unit, and Medical Research Council Soweto Matlosana
Collaborating Centre for HIV/AIDS and TB, University of the Witwatersrand, Johannesburg, South Africa,
9 Johns Hopkins University Center for TB Research, Baltimore, Maryland, United States of America,
10 Department of Science and Technology / National Research Foundation Centre of Excellence for
Biomedical TB Research, University of the Witwatersrand, Johannesburg, South Africa, 11 Division of
Public Health, Surveillance and Response, National Institute for Communicable Disease of the National
Health Laboratory Service, Johannesburg, South Africa, 12 Africa Health Research Institute, Durban, South
Africa, 13 Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, United
States of America, 14 University of KwaZulu-Natal, Durban, South Africa
* aaron.karat@lshtm.ac.uk
Abstract
Background
Early mortality among HIV-positive adults starting antiretroviral therapy (ART) remains high
in resource-limited settings, with tuberculosis (TB) the leading cause of death. However,
current methods to estimate TB-related deaths are inadequate and most autopsy studies
do not adequately represent those attending primary health clinics (PHCs). This study
aimed to determine the autopsy prevalence of TB and other infections in adults enrolled at
South African PHCs in the context of a pragmatic trial of empiric TB treatment (“TB Fast
Track”).
Methods and Findings
Adults with CD4150 cells/μL, not on ART or TB treatment, were enrolled to TB Fast
Track and followed up for at least six months. Minimally invasive autopsy (MIA) was con-
ducted as soon as possible after death. Lungs, liver, and spleen were biopsied; blood,
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CSF, and urine aspirated; and bronchoalveolar lavage fluid obtained. Samples underwent
mycobacterial, bacterial, and fungal culture; molecular testing (including Xpert®MTB/RIF);
and histological examination. 34 MIAs were conducted: 18 (53%) decedents were female;
median age was 39 (interquartile range 33–44) years; 25 (74%) deaths occurred in hospi-
tals; median time from death to MIA was five (IQR 3–6) days. 16/34 (47%) had evidence of
TB (14/16 [88%] with extrapulmonary disease; 6/16 [38%] not started on treatment ante-
mortem); 23 (68%) had clinically important bacterial infections; four (12%) cryptococcal dis-
ease; three (9%) non-tuberculous mycobacterial disease; and two (6%) Pneumocystis
pneumonia. Twenty decedents (59%) had evidence of two or more concurrent infections; 9/
16 (56%) individuals with TB had evidence of bacterial disease and two (13%) cryptococcal
disease.
Conclusions
TB, followed by bacterial infections, were the leading findings at autopsy among adults with
advanced HIV enrolled from primary care clinics. To reduce mortality, strategies are
needed to identify and direct those at highest risk into a structured pathway that includes
expedited investigation and/or treatment of TB and other infections.
Background
Mortality among HIV-positive adults prior to starting and in the first year of antiretroviral
therapy (ART) remains high, particularly among those with advanced disease in resource-con-
strained settings [1–3]. Pathological autopsy studies involving HIV-positive individuals have
consistently found tuberculosis (TB) to be the leading cause of death and the overall prevalence
of active TB to be extremely high, much of it undiagnosed antemortem [4–7]. TheWorld
Health Organization (WHO) aims to reduce TB deaths by 95% by 2035 [8], but questions
remain around current estimates of TB deaths and the methods used to obtain them [9]. Death
certification in many parts of sub-Saharan Africa remains sub-optimal [10,11] and the short-
comings of verbal autopsy, a structured interviewwith the family or carers of the deceased, in
classifyingHIV-related deaths are well documented [12–14]. Pathological autopsy studies pro-
vide the most accurate estimates, but almost all have only included individuals recruited after
admission to hospital and do not necessarily represent the broader population who receive the
majority of their care from primary health clinics and may die outside of hospitals [15]. Robust
data on the prevalence of TB in deceasedHIV-positive individuals and more accurate cause of
death estimates are essential in measuring progress towards the reduction and eventual elimi-
nation of TB-related deaths and in the design of interventions to reduce mortality in this popu-
lation [16].
Full pathological autopsy with visualisation and sampling of all organs remains the gold
standard for assigning cause of death [17,18], but it is expensive, time consuming, and not well
accepted by families, who are often required to provide consent [19]. There is growing evidence
that minimally invasive autopsy (MIA) can provide useful information relevant to cause of
death, particularly with regards to TB and other infectious diseases [20,21]; one study, involv-
ing 96 HIV-positive adults in Uganda, compared histology fromMIA to that from full autopsy
and found that MIA was 71% sensitive and 100% specific in detecting TB [18]. Adding culture
and/or other bacteriologicalmodalities to MIA would likely improve its sensitivity in this
regard. The acceptance of MIA among recently bereaved families is considerably higher than
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for full autopsy [5,22]; it is safer, cheaper, and procedures can be conducted outside of hospi-
tals, in private mortuaries or other locations [23]. This study aimed to determine the autopsy
prevalence of TB and other treatable infections in adults with advanced HIV disease recruited
in public sector primary health care facilities who died after enrolment to a pragmatic trial of
empiric TB treatment (“TB Fast Track”) [24].
Methods
Study population
The TB Fast Track study, described in detail elsewhere [24], was a cluster-randomised trial of
targeted empirical TB treatment enrolling adults with CD4150 cells/μL, not on TB treatment
or ART at the point of enrolment, attending one of twenty-four public sector primary health
clinics in three provinces of South Africa. At intervention sites, individuals were assessed for
their probability of active TB disease using an experimental algorithm that included the results
of point-of-care tests. Those considered ‘high’ probability were started on TB treatment imme-
diately, followed by ART within two weeks; those considered ‘medium’ probability were further
investigated; and those considered ‘low’ probability initiated ART immediately. Participants at
control sites followed standard clinic procedures. All participants were followed up for at least
six months. If the study team became aware of a participant’s death before the funeral had
taken place, the family’s permission was sought to undertakeMIA. Efforts were made to con-
duct autopsies as soon as possible after death, but no limits were placed on the time that could
elapse between death and autopsy.
Autopsy procedures
Four organs were targeted for tissue biopsy: liver, spleen, and right and left lungs. Where possi-
ble, ultrasoundwas used to check for liver lesions and pleural effusions and to locate the spleen.
Any lesions or effusions found were targeted during sampling. The skin overlying all sampling
sites was cleaned using 70% isopropyl alcohol and 10% povidone iodine. Using 18 gauge core-
biopsy needles, a minimum of five samples, each approximately 2cm in length, were taken
from each site for each of bacterial and fungal microscopy and culture; mycobacterial culture;
and histology. Cerebrospinal fluid (CSF) was extracted by insertion of a 22 gauge spinal needle
inferior to the occipital base in the direction of the eyes to access the cerebellomedullarycistern.
Flocked swabs were inserted into the oro- and naso-pharyngeal cavities and then immersed in
PrimeStore media (LonghornVaccines and Diagnostics, Bethesda,MD, USA). Bloodwas aspi-
rated from the right subclavian or internal jugular vein and a urinary catheter was used to col-
lect residual urine. Modified bronchoalveolar lavage (BAL) was conducted by instilling 80-
120ml of 0.9% saline through a horizontal incision of the cricothyroid membrane using a 16
gauge nasogastric tube inserted into the trachea in the direction of the lungs. Enlarged lymph
nodes and skin lesions in areas other than the face were sampled by needle biopsy or scalpel
excision, respectively.
As far as possible, MIA was conducted by a single, clinically-trainedoperator. If the primary
operator was unavailable, limitedMIA, without ultrasound or any attempt to obtain blood,
urine, or BAL, was conducted by a non-clinical operator.
Laboratory procedures
All tissue samples, as well as CSF, urine, and BAL were cultured for mycobacteria usingMyco-
bacterial Growth Indicator Tube (MGIT) culture (BectonDickinsonMicrobiology Systems,
Cockeysville,MD, USA). Culture-positive samples underwentmicroscopy with Ziehl-Neelsen
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(ZN) staining and polymerase chain reaction (PCR) testing for speciation and drug resistance
(Hain LifescienceGmbH, Germany). Xpert1 MTB/RIF (Cepheid, Sunnyvale, CA, USA) and
microscopy of immunofluorescence-stained slides for Pneumocystis jirovecii were performed
on BAL samples. Tissue samples, as well as CSF, blood, and BAL, underwentmicroscopy,
Gram staining, and aerobic culture for bacteria and fungi. Real-time PCR assays were used to
detect Streptococcus pneumoniae, Neisseria meningitidis, andHaemophilus influenzae in CSF
and blood [25,26]; and Legionella spp.,Mycoplasma pneumoniae, Chlamydia pneumoniae [27],
and Bordetella spp. [28] in naso-/oro-pharyngeal and BAL specimens. Naso-/oro-pharyngeal
and BAL specimens were further tested by multiplex real-time reverse transcription PCR for
parainfluenza viruses 1–3, adenovirus, enterovirus, human metapneumovirus, respiratory
syncytial virus, rhinovirus, influenza A virus, and influenza B virus [29]. CSF was tested for
the presence of parvovirusB19, cytomegalovirus (CMV), Epstein Barr virus (EBV), herpes sim-
plex virus 1–2, human herpes viruses 6 and 7, and parechoviruses (FTDNeuro 9 assay, Fast-
track diagnostics Ltd., Malta). Urine was tested for Legionella pneumophila serogroup 1 and S.
pneumoniae antigen (BinaxNOW, Alere, Waltham, MA, USA). Histological examination was
carried out on all tissue samples, using ZN and Grocott stains for the identification of myco-
bacteria and fungi, respectively. Other stains and PCR procedures were performed as necessary,
based on pathologist assessment.
Ethics
Separate approvals for the autopsy sub-study were obtained from the Research Ethics Commit-
tees of the London School of Hygiene & Tropical Medicine and The University of theWitwa-
tersrand. Beginning in August 2013, participants in TB Fast Track were asked to give written
informed consent for MIA if they should die during the parent study. Declining permission to
take part in the autopsy sub-study did not affect their participation in TB Fast Track or their
routine health care. If a participant who had given their written consent died during follow-up,
verbal agreement from the next of kin was obtained to proceed with MIA. For participants who
were enrolled to TB Fast Track prior to August 2013 and died during follow-up, formal written
consent to undertakeMIA was sought from the next of kin.
Data interpretation and statistical analysis
Data were entered into EpiData v3.1 (The EpiData Association, Odense, Denmark) and ana-
lysed using Stata v14 (StataCorp, College Station, TX, USA). Baseline demographics were com-
pared using chi-square or Kruskal-Wallis tests, as appropriate. Analysis was conducted in
order to estimate the autopsy prevalence of identified pathogens only; no inference was made
as to possible cause(s) of death, which will be reported elsewhere.Microscopy and culture
results were interpreted by experiencedmicrobiologists who reviewed the data and designated,
for each decedent, which organisms were considered ‘artefact’ and which ‘pathogenic’. For all
decedents, Enterococcus spp., Enterobacter spp., E. coli, Proteus spp., Bacillus spp., coagulase
negative staphylococci, and Viridans streptococci were considered artefact. Additionally,
Gram-negative organisms isolated only from the spleen of a decedent were considered artefact
due to the high likelihood of contamination from abdominal viscera.
Results
Consent, demographics, and samples obtained
From December 2012 to December 2014, a total of 3022 individuals were enrolled into the TB
Fast Track study: 626 (20.7%) were enrolled prior to autopsy sub-study initiation and were not
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asked to consent at the point of enrolment. Of the remaining 2396 individuals, 1675 (69.9%)
consented to autopsy at enrolment. A total of 364 TB Fast Track participants died after enrol-
ment to the study, 285 (78%) within six months. Seventy-five of 364 (21%) deaths occurred
prior to sub-study initiation and 229 (63%) were ascertained after burial, leaving 60 (16%) indi-
viduals for whom death was ascertained in time for MIA. Of these 60, 14 (23%) had already
declined to participate and for three (5%) no family member could be contacted. Between
October 2013 and June 2015, 43 families were approached in person for permission to conduct
an autopsy: 36 (84%) gave their consent. Two autopsies did not proceed due to refusal by the
mortuary; 34 autopsies were therefore conducted.
Decedents included in the MIA study are described in Table 1. Just over half the decedents
(18/34 [53%]) were female; median age was 39 (interquartile range [IQR] 33–44) years; all
were Black African; 32 (94%) were South African, with one (3%) from each of Lesotho and
Mozambique; 13 (38%) individuals had completed South African grade 12 (high school) or
equivalent; 17 (50%) were in some form of employment at the point of enrolment; and, of the
24 individuals able to estimate their household income at enrolment, 15 (63%) reported it to be
less than R2000 (~USD150) per month. The majority of individuals died in hospitals (25/34
[74%]), the remainder died in the community; median time from enrolment to death was 60
(IQR 21–175) days; and 28 (82%) individuals died within six months of enrolment. The
median CD4 count at enrolment was 34 (IQR 17–66) cells/μL. Twenty (59%) decedents were
started on TB treatment a median 60 (IQR 26–175) days prior to death: 15/20 (75%) were
enrolled to the intervention arm of the TB Fast Track study and 12 (80%) of these were started
on TB treatment based on the study algorithm. Twenty-five (74%) decedents were initiated on
ART a median 74 (IQR 30–126) days before death; 28 (82%) started co-trimoxazole prophy-
laxis at least one week before death; and one (3%) isoniazid preventative therapy at least one
week before death. A comparison of baseline characteristics between individuals who had an
MIA conducted (n = 34) and those who died within six months of enrolment but did not have
an MIA (n = 259) showed only one important difference, in the proportion who started TB
treatment between enrolment and death (59% inMIA group and 31% in group with no MIA;
p = 0.001).
The primary operator conducted 31/34 (91%) MIA; median time from death to MIA was
five (IQR 3–6) days; and 33/34 (97%) MIA were conducted within 10 days of death. Measured
by histological examination, overall success rates in obtaining samples varied by site: 33/34
(97%) attempted lung biopsies were successful, compared to 30/34 (88%) liver and 21/34
(62%) splenic biopsies; 30/31 (97%), and 30/32 (94%) attempts to obtain BAL and CSF, respec-
tively, were successful (S1 Table).
Tuberculosis
Evidence of TB disease was found in 16/34 (47%) decedents (Table 2), of whom 12 (75%) had
evidence on histology (Fig 1); 11 (69%) on culture; five (31%) on testing with Xpert1 MTB/
RIF; and eight (50%) on histology plus bacteriology. Almost all (14/16 [88%]) decedents with
evidence of TB had extrapulmonary disease; 3/14 (21%) had no evidence of pulmonary disease.
BAL specimens provided the highest yield for culture (seven positive), followed by CSF and
splenic tissue (five each), and lung and liver tissue (four each; S1 Table). Twelve decedents had
histological evidence of TB: four (33%) in all of lungs, liver, and spleen; two (17%) in lungs and
liver only; two (17%) in liver and spleen only; and two (17%) in lungs alone. A total of 164 sam-
ples underwentmycobacterial culture: 37 (23%) were positive and 13 (8%) could not be inter-
preted due to bacterial contamination. Of the 16 individuals with autopsy evidence of TB, 10
(63%) were started on TB treatment a median 56 (IQR 40–173) days before death; 14 (88%)
Autopsy Prevalence of TB in HIV-Positive Adults in South Africa
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received ART, initiated a median 65 (IQR 30–126) days before death; and nine (56%) were ini-
tiated on both TB treatment and ART. Six (38%) individuals with autopsy evidence of TB were
not started on TB treatment antemortem, five of whom were enrolled to the control arm of TB
Fast Track.
Infections with non-tuberculous mycobacteria and other bacteria
Of the 34 decedents, three (9%) had evidence of disease caused by non-tuberculousmycobacte-
ria (NTM): two grewMycobacterium avium and one grewMycobacterium intracellulare from
multiple sites. Excluding mycobacteria and organisms considered artefact, 23/34 (68%) dece-
dents had culture evidence of pathogenic bacterial infections: 14/23 (61%) grewKlebsiella spp.
from non-splenic samples; four (17%) grew S. aureus; two (9%) grew Pseudomonas spp.; and S.
pneumoniae, Salmonella sp., Nocardia sp., andHaemophilus sp. were cultured from one (4%)
Table 1. Baseline characteristics of deceased TB Fast Track participants: MIA conducted (n = 34) vs no MIA (n = 259).
Characteristics MIA conducted (n = 34) n (%) or
median (IQR)
No MIA conducted (n = 259) n (%) or
median (IQR)
p value (Chi2 or Kruskal-
Wallis)
Demographics and past medical
history
Female 18 (53) 133 (51) 0.86
Age (years) 39 (33–44) 39 (34–46) 0.57
CD4 count at enrolment (cells/μL) 34 (17–66) 45 (21–88) 0.21
Black African 34 (100) 257 (99) 0.61
South African 32 (94) 242 (93) 0.88
Enrolled in a peri-urban area 23 (68) 187 (72) 0.58
Completed grade 12 13 (38) 82 (32) 0.44
Employed at time of enrolment 17 (50) 106 (41) 0.31
Household income ofR2000 per
month*
15 (63) (n = 24) 90 (47) (n = 190) 0.16
Previously diagnosed with chronic
illness**
5 (15) 34 (13) 0.80
Smoking history 7 (21) (n = 33) 51 (20) (n = 257) 0.85
Previous treatment for TB 6 (18) 27 (10) 0.21
Symptoms at enrolment
Cough 14 (41) 127 (49) 0.39
Night sweats 11 (32) 85 (33) 0.96
Fever 11 (32) 73 (28) 0.61
Weight loss 28 (88) (n = 32) 205 (84) (n = 244) 0.61
Assessment at enrolment
Body-mass index (kg/m2) 20.2 (18.7–23.2) 20.2 (17.7–23.6) 0.48
Positive urine LAM (point of care) † 10 (29) 74 (29) 0.92
Between enrolment and death
Started TB treatment 20 (59) 79 (31) 0.001
Started ART 25 (74) 153 (59) 0.10
Time from enrolment to death
(days)
60 (21–175) 60 (31–113) 0.72
*Ten decedents in the MIA group and 69 in the no MIA group did not know their average household monthly income.
**Chronic illness included hypertension, diabetes, asthma, epilepsy, cancer, and cardiac, renal, and chronic lung disease.
†Samples that elicited one or more visible lines on the LAM test strip were considered positive.
ART: antiretroviral therapy; IQR: interquartile range; LAM: lipoarabinomannan; MIA: minimally-invasive autopsy; TB: tuberculosis
doi:10.1371/journal.pone.0166158.t001
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Table 2. Combined histopathological and microbiological findings; participants with evidence of each at autopsy; and demographics for select
groups (n = 34).
Pathogen Decedents with autopsy evidence of Age at death (years)
Median (IQR or
range*)
CD4 count at enrolment
(cells/μL) Median (IQR or
range*)
Time from enrolment to
death (days) Median (IQR or
range*)Major diseasecategory
Major disease
category n (%/34)
Disease sub-
category n (row
%)Disease sub-
category
All decedents - - 39 (33–44) 34 (17–66) 60 (21–175)
Mycobacteria
Tuberculosis 16 (47) - 38 (33–43) 44 (21–60) 63 (40–152)
Pulmonary only 2 (13)
Extrapulmonary only 3 (19)
Pulmonary &
extrapulmonary
11 (69)
Rifampicin-resistant 2 (13)
Non-tuberculous
mycobacteria
3 (9) 45 (27–56) 2 (2–7) 33 (21–324)
Disseminated 3 (100)
Bacteria†
Any bacterial
infection
23 (68) 40 (34–45) 33 (10–75) 57 (21–184)
Pneumonia 11 (32) 41 (38–54) 33 (17–36) 33 (14–285)
Gram-negative 6
Gram-positive 5
Organism unclear 1
Bacteria in CSF 4 (12) 40 (31–54) 106 (66–132) 82 (8–285)
S. pneumoniae 3
S. aureus 1
Salmonella sp. 1
Bacteraemia 3 (9) 33 (31–36) 106 (29–132) 100 (8–184)
H. influenzae 1
K. pneumoniae 1
Salmonella sp. 1
S. aureus 1
S. pneumoniae 1
Fungi & viruses‡
Pneumonitis 4 (12) 38 (29–44) 86 (17–106) 67 (14–304)
Cryptococcal disease 4 (12) 40 (29–46) 8 (1–56) 53 (10–373)
Disseminated 2 (50)
Pneumocystis
pneumonia
2 (6) 40 (39–41) 41 (3–78) 133 (84–182)
CMV disease 2 (6) 33 (33–34) 20 (10–29) 106 (28–184)
Disseminated 2 (100)
Other/non-infectious
Hepatic 18 (53) 40 (34–45) 29 (17–56) 91 (33–184)
Steatosis 12 (67)
Non-specific portal
triaditis
6 (33)
Chronic hepatitis?
viral
4 (22)
Acute hepatitis 3 (28)
(Continued )
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decedent each. Pathogenic bacteria were most frequently isolated from BAL samples (18 posi-
tive cultures) and lung tissue (12 positive; S1 Table). Of the 33 decedents with lung tissue avail-
able for histological examination, 11 (33%) had microscopic evidence of bacterial pneumonia
(Table 2), nine (82%) of whom also grew pathogenic bacteria from BAL and/or lung tissue,
most frequently Klebsiella spp.. Of the 30 decedents with CSF samples, two (7%) were culture
positive, one growing Salmonella sp. and the other S. aureus and S. pneumoniae.
Bacterial PCR was conducted on 13 CSF samples and 10 blood samples: S. pneumoniae was
detected in 3/13 (23%) CSF samples and 1/10 (10%) blood sample; andH. influenzae was
detected in 1/10 (10%) blood sample. PCR of 11 BAL specimens and 13 naso-/oropharyngeal
swabs for atypical pneumonia-causing pathogens and Bordetella spp. and testing of seven urine
samples for Legionella pneumophila and pneumococcal antigen yielded no positive results (S1
Table).
Cryptococcal disease
Evidence of cryptococcaldisease was found in 4/34 (12%) decedents with enrolment CD4
counts ranging from 1–56 cells/μL and time from enrolment to death 10–373 days. Three
(75%) decedents had histological evidence of cryptococcaldisease (Fig 1), two in more than
one organ, and Cryptococcus neoformans was grown from two (50%) decedents, one from
lungs and the other from liver and CSF. Two decedents were treated for cryptococcosisprior to
death, receiving 800mg oral fluconazole for four days and 800mg intravenous fluconazole for
one day, respectively (decedents 02 and 05; S2 Table).
Other fungal and viral infections
Two of 34 (6%) decedents had evidence of cytomegalovirus (CMV) disease on histological
examination, both with disseminated disease, and a further two (6%) had evidence of Pneumo-
cystis pneumonia (PCP; Table 2; Fig 1). Viral PCR assays were conducted on specimens from
14/34 (41%) decedents (S1 Table). Of the 13 with BAL specimens and/or naso-/oropharyngeal
swabs available for viral testing, rhinovirus was detected four (31%) times and influenza virus
and respiratory syncytial virus detected once each (8%). CSF samples from 11 decedents were
available for viral testing, EBV was detected eight times (73%), CMV seven times (64%); parvo-
virus B19 twice (18%); and influenza A virus, human-Herpes virus 7, and varicella zoster virus
once each (9%).
Table 2. (Continued)
Pathogen Decedents with autopsy evidence of Age at death (years)
Median (IQR or
range*)
CD4 count at enrolment
(cells/μL) Median (IQR or
range*)
Time from enrolment to
death (days) Median (IQR or
range*)Major diseasecategory
Major disease
category n (%/34)
Disease sub-
category n (row
%)Disease sub-
category
Renal 6 (18) 42 (23–62) 19 (1–107) 49 (9–324)
Acute tubular
necrosis
3 (50)
Interstitial nephritis 5 (83)
*IQR shown if n10; range shown if n<10
†Some decedents had more than one pathogenic organism identified
‡Positive viral PCR was not considered sufficient evidence of disease
CMV: cytomegalovirus; CSF: cerebrospinal fluid; IQR: interquartile range; MIA: minimally-invasive autopsy
doi:10.1371/journal.pone.0166158.t002
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Decedents with multiple pathogens identified
Twenty (59%) decedents had either histological or culture evidence of at least two infections
present at the same or different sites (Fig 2). Of the 16 decedents with evidence of TB, nine
(56%) had evidence of bacterial disease at one or more sites; two (13%) had evidence of crypto-
coccal disease; and one (6%) each had evidence of CMV disease (Fig 1), PCP, and disease due
Fig 1. Six examples of histological changes observed in MIA tissue samples (n = 4). Panels (A), (B), and (C)
demonstrate mycobacterial and CMV disease in the lung and liver of decedent 08: (A) necrotising, intra-alveolar
granuloma with superadded CMV nuclear inclusions (lung; H&E x40); (B) numerous acid-fast bacilli (lung; ZN
x40); and (C) mycobacterial granuloma (liver; H&E x20). Panel (D) demonstrates polymorphous cryptococcal
yeasts in alveolar spaces (decedent 19; lung; Grocott’s methenamine silver x40). Panel (E) illustrates the
characteristic small, crescenteric, yeast-like fungi of Pneumocystis jirovecii pneumonia (decedent 11; lung;
Grocott’s methenamine silver x40). Panel (F) shows active hepatitis B virus infection (decedent 34; liver; H&E
x40). CMV: cytomegalovirus; H&E: haematoxylin and eosin; MIA: minimally invasive autopsy; ZN: Ziehl-Neelsen
doi:10.1371/journal.pone.0166158.g001
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to NTM. Of the 23 decedents with evidence of bacterial infections, three (13%) also had evi-
dence of cryptococcaldisease; two (9%) disease due to CMV; two (9%) disease due to non-
tuberculousmycobacteria; one (4%) due to PCP; and four (17%) due to diseases caused by
other viruses.
Additional findings
Liver tissue from 30 decedents underwent histological examination,18 (60%) showed evidence
of inflammation: 5/18 (28%) had acute or chronic hepatitis, four of which were thought likely
to be viral in origin (Fig 1); 12/18 (67%) had evidence of steatosis, one with non-alcoholic
steato-hepatitis; and 6/18 (33%) had evidence of non-specific portal triaditis. Renal samples
were also collected incidentally (nine from the right kidney, thirteen from the left): 6/13 (46%)
decedents showed evidence of interstitial nephritis (n = 5) and/or acute tubular necrosis (n = 3)
in one or both kidneys (Table 2).
Discussion
To our knowledge this is the first study that has followed up a prospective cohort of HIV-posi-
tive outpatients conductingminimally invasive autopsies on those who died. This study is also
Fig 2. Venn diagram illustrating overlap between diagnoses made at autopsy: any active TB; extrapulmonary TB; any bacterial infection;
bacterial pneumonia; disease due to non-tuberculous mycobacteria; cryptococcal disease; and Pneumocystis pneumonia (n = 31*).
*Figure only includes decedents with autopsy evidence of disease due to specified pathogens
doi:10.1371/journal.pone.0166158.g002
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unusual in that it includes a number of deaths that occurred outside hospitals, thereby includ-
ing individuals not well represented in previous autopsy studies of HIV-positive individuals.
Disease prevalence and overlap
We conductedMIA on as many TB Fast Track decedents as possible, all of whomwere not tak-
ing ART or TB treatment at the time of enrolment. Those who had MIA and those who did not
were largely similar with regard to characteristics at enrolment and during follow up, although
those with MIA were more likely to have been treated for TB between enrolment and death.
This, together with the likelihood that MIA will miss some cases that may be identified by full
autopsy [18], suggests that the prevalence of TB at death among the entire population of dece-
dents in TB Fast Track may have been even higher than the almost 50% found in this sample.
Nearly 90% of those with evidence of TB had disease in at least one extrapulmonary site and
38% were not on TB treatment at the time of death. These findings, in line with data published
by Omar et al. [5], suggest that TB is as frequent a pathogen among those attending primary
care clinics as it is among the in-patients previously investigated in autopsy studies. Our find-
ings are consistent with most autopsy studies done in sub-Saharan Africa over the last 20 years
[4–6]. A recent systematic review [6] found the pooled prevalence of TB at autopsy in HIV-
positive adults to be 39.7%, of which 87.9% was extrapulmonary and/or disseminated and
45.8% was not diagnosed before death. The review included four studies conducted during the
ART era and, though overall ART coverage was not included, TB prevalence in these four stud-
ies was equal to or greater than in studies conducted prior to ART rollout, suggesting that indi-
viduals are initiating ART too late or are not linked to treatment at all. Studies conducted in
clinics in South Africa have previously highlighted the large burden of undiagnosedTB among
the ambulatory HIV-positive population [30,31], but investigation for TB is largely based on
reporting respiratory symptoms, using sputum-based diagnostic tests [32,33]. A recent study
conducted in Cape Town found that, of 139 HIV-positive individuals diagnosedwith TB dur-
ing admission to hospital (median CD4 count 80 cells/μL; 35% on ART for a median 1.3 years),
115 (83%) had at least one non-respiratory sample that was positive on testing with Xpert1
MTB/RIF, or culture positive forM. tuberculosis [34]. Non-respiratory samples included
blood, urine, and CSF. WHO recommends Xpert1 MTB/RIF for use on extrapulmonary sam-
ples [35]. However, there are formidable practical and financial challenges in establishing alter-
native diagnostic algorithms and care pathways in primary care in resource-limited settings, in
particular, the lack of a sensitive, cost-effective, point-of-care diagnostic test, and the difficulties
in obtaining suitable specimens samples in individuals who cannot produce sputum. Regard-
less, the data suggest that these are obstacles that must be overcome in order to achieve any
meaningful reduction in TB mortality.
A striking finding in our study was the high proportion of decedents with evidence of two
or more infections at autopsy, sometimes at different sites, or concurrent at the same site.
These are similar to results from a study conducted in 2009 among 39 HIV-positive ART-eligi-
ble adults in a hospital in South Africa [36], which attributed a third of deaths to bacterial
infections, with several decedents showing evidence of multiple infections. Another study,
involving full autopsy on adults (16 years) in a tertiary hospital in Zambia, 101 of whom were
HIV-positive, found that 39/101 (39%) had autopsy evidence of ‘pyogenic pneumonia’, with
21/39 (54%) also showing evidence of active TB disease [4]. Among decedents in our study,
most bacterial infections were due to common pathogens, such as Klebsiella spp., Salmonella
spp., H. influenzae, and S. aureus. More needs to be done, through increased awareness among
clinicians and in the design of clinical guidelines, to target and treat other opportunistic infec-
tions in those with advanced disease, even those already receiving prophylaxis, TB treatment,
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or ART. Longer term, initiating ART at higher CD4 counts will help reduce the likelihood of
progression to this stage of advanced disease; recent guidelines advocating ART in all people
living with HIV are an important step towards making this a reality [37].
Interpretation of autopsy findings
M. tuberculosis can survive for years after the death of an infected individual and after preserva-
tion in formalin [38,39]. In our cohort, seven (64%) of the 11 individuals withM. tuberculosis
culture-positive samples had received TB treatment for a median 122 (IQR 48–176) days. The
interpretation of culture results from autopsy specimens is not straightforward and may be
complicated furtherwhen the procedure is conductedmany days after death, potentially pro-
viding greater opportunity for tissue autolysis and translocation of organisms to compartments
they did not occupy in life [40–42]. However, there is evidence to show that the time from
death to autopsy does not have a major effect on false-positive bacterial results if the body is
kept refrigerated [43,44]. One study, conducted among 507 infants with sudden and unex-
pected deaths, even suggests that a longer interval may allow for fewer false-positive results
[45]; and there are reports of pathogens recovered from bodies in states of advanced decompo-
sition [46,47]. In our study, samples from all sites, except CSF, grew some organisms that were
likely artefact (S1 Table); data from each decedent were reviewed individually by a microbiolo-
gist to decide on likely contaminants. This further highlights the challenges faced in assigning
causes of death in these individuals, in whommany pathogens may cause disease at one time.
Results of any microbiological tests, including mycobacterial, must be reviewedwith clinical
history and, ideally, histology in order to more accurately estimate prevalence of active disease
and/or cause of death. The development of standardised guidelines to this end is suggested.
MIA in surveillance
The consistent under-diagnosis of TB ante mortem [6] suggests that MIA may have a role in
routine surveillance to estimate TB prevalence at death more accurately. If MIA was to be sim-
plified for this purpose, our data suggest that respiratory samples (BAL and lung tissue) would
provide the highest yield for TB diagnosis. Combining BAL Xpert1 MTB/RIF with BAL
mycobacterial culture would have detected nine of our TB cases; adding mycobacterial culture
of lung tissue would add a further two; and histological examination of lung tissue a further
three; accounting for 88% of the TB seen in our decedents. The role of Xpert1 MTB/RIF as
part of the autopsy process is not established: a recent study testing post mortem liver, lung,
and brain tissue found that it detected TB in 7/8 (87.5%) cases, although the gold standard
used was another PCR technique, rather than liquid culture [21]. In our study, only 5/14
(35.7%) decedents with BAL specimens and evidence of TB had a positive Xpert1 MTB/RIF,
though this test was done only on BAL specimens, whereas culture and histology were con-
ducted on specimens frommany other anatomical sites, many of them extrapulmonary. There
were three decedents whose BAL specimens were Xpert1 MTB/RIF negative, but culture posi-
tive for MTB (decedents 2, 4, and 33; S2 Table). More work is needed to establish the optimum
use of this and other molecular techniques in post mortem specimens.
This study has limitations: autopsy coverage of deaths occurring among participants in TB
Fast Track was low, at around 10%, but those included appear largely representative of all
those who died. AlthoughMIA provides less information than complete autopsy, particularly
with regards to non-infectious diagnoses, its greater acceptability to families and participants is
a major advantage; and it was not possible for one operator to conduct all 34 MIAs, leading to
some variability in tissue sampling. Strengths of the study include being nested within a trial
that recruited a widely representative sample of adults with advanced HIV disease at high risk
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of active TB; mycobacterial culture and histology being conducted on all decedents; and sam-
ples from different anatomical sites being individually tested, which may provide guidance for
future MIA-based surveillanceprogrammes.
Conclusions
The autopsy prevalence of tuberculosis among adults with advanced HIV disease who die
before initiating ART or early on ART is high and is likely a major contributor to mortality.
The large proportion of individuals with autopsy evidence of potentially treatable bacterial
and/or fungal infections, often in addition to TB, should be considered when assessing these
high-risk patients in primary or secondary care. Evidence-based interventions are urgently
needed that prioritise timely and thorough investigation for those with advanced HIV disease;
allow for empiric treatment when indicated; and promote early initiation of ART.
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